May 29-June 1, 2024 | Vancouver, Canada
The OmniaBio team will be attending and presenting at the ISCT 2024 Annual Meeting. As a technology-driven and specialized cell and gene therapy CDMO with extensive experience navigating complex challenges, we can help you advance your program.
Visit Booth #226
Our team looks forward to seeing you very soon in Vancouver.
Book a Meeting
Schedule a meeting with us at the show by using the ISCT partnering app or by completing this Book Now form.
Attend Our Corporate Session | Friday, May 31, 2024 | 5:00–6:00 p.m.
Streamlining Your Path to Market: Leveraging the Latest CAR T Cell Technologies and Enabling Tools
Panel will discuss commercialization challenges for CAR T cell therapies and how to streamline CAR T cell therapy commercialization through manufacturing intensification and enabling tools.
Meet Our Panelists
Join Poster Networking Session #1 | Wednesday, May 29, from 7:00–8:30 p.m.
Connect with our technical experts during the poster networking session:- High Throughput Screening of Lipid Nanoparticles for Enhanced Drug Delivery to Immune Cells | Poster #846 | Presenter: Vlada Sadetckaia, Associate Scientist I, CCRM
- Transduction and expansion of Natural Killer cells using stirred-tank bioreactors | Poster #947 | Presenter: Tey Irrazabal, PhD, Lead Scientist I, CCRM
- Multi Gene Editing of iPSCs with Novel Transfection Platform Solupore® for generation of efficiently edited and healthy iPSC lines | Poster #1139 | Presenter: Bilal Mughal, PhD, Lead Scientist, CCRM
- Optimizing Lentiviral Vector Production for Cell Therapies: Advancing Manufacturing Strategies at OmniaBio | Poster #1143 | Presenter: Adam Huys, PhD, Director, Process and Analytical Development, CCRM
About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
